Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis
Open Access
- 7 November 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 19 (4), 951-959
- https://doi.org/10.1007/s00330-008-1211-7
Abstract
Radioembolization with yttrium-90 microspheres (90Y-RE), either glass- or resin-based, is increasingly applied in patients with unresectable liver malignancies. Clinical results are promising but overall response and survival are not yet known. Therefore a meta-analysis on tumor response and survival in patients who underwent 90Y-RE was conducted. Based on an extensive literature search, six groups were formed. Determinants were cancer type, microsphere type, chemotherapy protocol used, and stage (deployment in first-line or as salvage therapy). For colorectal liver metastases (mCRC), in a salvage setting, response was 79% for 90Y-RE combined with 5-fluorouracil/leucovorin (5-FU/LV), and 79% when combined with 5-FU/LV/oxaliplatin or 5-FU/LV/irinotecan, and in a first-line setting 91% and 91%, respectively. For hepatocellular carcinoma (HCC), response was 89% for resin microspheres and 78% for glass microspheres. No statistical method is available to assess median survival based on data presented in the literature. In mCRC, 90Y-RE delivers high response rates, especially if used neoadjuvant to chemotherapy. In HCC, 90Y-RE with resin microspheres is significantly more effective than 90Y-RE with glass microspheres. The impact on survival will become known only when the results of phase III studies are published.This publication has 61 references indexed in Scilit:
- Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE StudyJournal of Clinical Oncology, 2008
- Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncologyEuropean Radiology, 2008
- The Toxicity of Liver Directed Yttrium-90 Microspheres in Primary and Metastatic Liver TumorsCancer Investigation, 2008
- Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: The tumor selectivity of the treatment as a function of tumor to liver flow ratioJournal of Translational Medicine, 2007
- Radioembolization with Yttrium-90 Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver MalignanciesJournal of Vascular and Interventional Radiology, 2006
- SELECTIVE INTERNAL RADIATION THERAPY WITH 90Y MICROSPHERES FOR COLORECTAL LIVER METASTASES: SINGLE-CENTRE EXPERIENCE WITH 100 PATIENTSAnz Journal of Surgery, 2006
- Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignanciesInternal Medicine Journal, 2005
- Selective Internal Radiation Therapy with SIR-Spheres® in Patients with Nonresectable Liver TumorsCancer Biotherapy & Radiopharmaceuticals, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- REGRESSION OF LIVER METASTASES FOLLOWING TREATMENT WITH YTTRIUM‐90 MICROSPHERESAnz Journal of Surgery, 1992